Ipsos Health Service Report 2026
Ipsos Health Service Report 2026

Ipsos Health Service Report 2026

Since 2018, Ipsos has been tracking perceptions of the quality of healthcare systems, the biggest health issues and the biggest public health problems.

Key Research Findings:

Ipsos Chart: 48% on average across 32 countries say mental health is the biggest health concern. This is up from 27% in 2018. Cancer, stress, obesity, and drug abuse follow as concerns. 50% across 32 countries have heard of GLP-1 drugs, such as Ozempic, Wegovy, Zepbound, Rybelsus or Mounjaro. 45% (on average) rate the quality of healthcare they receive as good. This ranges from 74% in Malaysia feeling their healthcare is good, to only 13% in Hungary.64% on average think their country’s healthcare system is currently overstretched. This ranges from 88% in Great Britain to 27% in South Korea. Perceived biggest healthcare problems: Access to treatment/waiting times 47%, Not enough staff 43%, Cost of accessing treatment 32%, Ageing population 23%, Bureaucracy 22%

 

Download the report below

 

Mental health remains the biggest health problem and is growing as a concern

On average across 32 countries one in two (48%) see mental health as one of the biggest health problems in their country ahead of cancer (40%), stress (32%) and obesity (25%). Mental health has topped our list of worries since 2023 and despite many already seeing it as a problem 19 out of the 28 countries surveyed this year and last are more likely to see it as major issue in 2026. 

Quality of care perceptions vary sharply around the world 

Malaysia tops our quality of care perceptions index with a score of 72%. While Hungary records the lowest score (28%). The quality of care perceptions index looks at people’s satisfaction with their country’s healthcare system, trust in the system, ability to access a doctor and a pharmacy, and whether the system treats all people equally.

Healthcare systems reach a breaking point for many Europeans 

A lack of capacity in health systems among countries in Europe is a growing worry. A majority see access to treatment and not enough staff as the biggest problems facing their healthcare systems (52% and 55% respectively). These figures are higher than the global averages (47% and 43%). They are much more likely (76%) to see their health services as overstretched than the global average (64%).

GLP-1s move from niche treatment to mainstream awareness 

Across 32 countries, one in two (50%) say they have heard of GLP-1s. This figure is higher in some of the world’s most advanced economies like Great Britain, Canada, or the US. While awareness is lower in LATAM, all 29 countries surveyed in 2025 and this year are more likely to be aware of GLP-1s in 2026. 
 

Contact

Related news